A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure
Abstract
:1. Introduction
2. Results
2.1. Construction of MAFLD Population Profile
2.2. Simulated Drug Exposure in MAFLD Population
2.3. Validation of the MAFLD Population Profile
2.3.1. Activity in Human In Vitro Models as Comparator
2.3.2. Activity in Pre-Clinical Animal Models as Comparator
3. Discussion
4. Methods
4.1. Construction of MAFLD Population Profile
4.1.1. Population Profile
4.1.2. Substrate Profiles
4.1.3. CYP Protein Abundance
4.1.4. Other Parameters
4.2. Simulated Drug Exposure in MAFLD Population
4.3. Validation of the MAFLD Population Profile
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Boeckmans, J.; Natale, A.; Buyl, K.; Rogiers, V.; De Kock, J.; Vanhaecke, T.; Rodrigues, R.M. Human-based systems: Mechanistic NASH modelling just around the corner? Pharmacol. Res. 2018, 134, 257–267. [Google Scholar] [CrossRef]
- Yilmaz, Y. Review article: Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther. 2012, 36, 815–823. [Google Scholar] [CrossRef]
- Adams, L.A.; Roberts, S.K.; Strasser, S.I.; Mahady, S.E.; Powell, E.; Estes, C.; Razavi, H.; George, J. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. J. Gastroenterol. Hepatol. 2020, 35, 1628–1635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Newman, L.A.; Sorich, M.J.; Rowland, A. Role of extracellular vesicles in the pathophysiology, diagnosis and tracking of non-alcoholic fatty liver disease. J. Clin. Med. 2020, 9, 2032. [Google Scholar] [CrossRef] [PubMed]
- Simon, T.G.; Roelstraete, B.; Khalili, H.; Hagström, H.; Ludvigsson, J.F. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort. Gut 2020, 70, 1375–1382. [Google Scholar] [CrossRef] [PubMed]
- Ando, Y.; Jou, J.H. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. Clinical Liver Disease. 2021, 17, 23–28. [Google Scholar] [CrossRef]
- Nebert, D.W.; Russell, D.W. Clinical importance of cytochromes P450. Lancet 2002, 360, 1155–1162. [Google Scholar] [CrossRef]
- Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013, 138, 103–141. [Google Scholar] [CrossRef]
- Li, H.; Clarke, J.D.; Dzierlenga, A.L.; Bear, J.; Goedken, M.J.; Cherrington, N.J. In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. J. Biochem. Mol. Toxicol. 2017, 31, e21840. [Google Scholar] [CrossRef] [Green Version]
- Kulkarni, N.M.; Malampati, S.; Mahat, M.Y.A.; Chandrasekaran, S.; Raghul, J.; Khan, A.A.; Krishnan, U.M.; Narayanan, S. Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. Drug Metab. Pers. Ther. 2016, 31, 165–171. [Google Scholar] [CrossRef]
- Bang, W.S.; Hwang, Y.R.; Li, Z.; Lee, I.; Kang, H.E. Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats. J. Pharm. Pharm. Sci. 2019, 22, 98–111. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Lee, S.H.; Jeong, H.J.; Kang, H.E. Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid. Xenobiotica 2021, 51, 324–334. [Google Scholar] [CrossRef]
- Wagner, C.; Zhao, P.; Pan, Y.; Hsu, V.; Grillo, J.; Huang, S.; Sinha, V. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: Report of an FDA public workshop on PBPK. CPT Pharmacomet. Syst. Pharmacol. 2015, 4, 226–230. [Google Scholar] [CrossRef]
- Zhang, X.; Yang, Y.; Grimstein, M.; Fan, J.; Grillo, J.A.; Huang, S.M.; Zhu, H.; Wang, Y. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018–2019 Submissions to the US FDA’s Office of Clinical Pharmacology. J. Clin. Pharmacol. 2020, 60, S160–S178. [Google Scholar] [CrossRef]
- Zhao, P. Report from the EMA Workshop on Qualification and Reporting of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation. CPT Pharmacomet. Syst. Pharmacol. 2016, 6, 71–72. [Google Scholar] [CrossRef] [Green Version]
- Zhao, P.; Zhang, L.; A Grillo, J.; Liu, Q.; Bullock, J.M.; Moon, Y.J.; Song, P.; Brar, S.S.; Madabushi, R.; Wu, T.C.; et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 2011, 89, 259–267. [Google Scholar] [CrossRef]
- Cheeti, S.; Budha, N.R.; Rajan, S.; Dresser, M.J.; Jin, J.Y. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm. Drug Dispos. 2013, 34, 141–154. [Google Scholar] [CrossRef]
- van Dyk, M.; Rowland, A. Physiologically-based pharmacokinetic modeling as an approach to evaluate the effect of covariates and drug-drug interactions on variability in epidermal growth factor receptor kinase inhibitor exposure. Transl. Cancer Res. 2017, 6, S1600–S1612. [Google Scholar] [CrossRef]
- Polasek, T.M.; Rayner, C.R.; Peck, R.W.; Rowland, A.; Kimko, H.; Rostami-Hodjegan, A. Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development. Clin. Pharmacol. Drug Dev. 2018, 8, 418–425. [Google Scholar] [CrossRef]
- Kapetas, A.; Sorich, M.; Rodrigues, A.R. Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic Cyotchrome P450 (CYP) 3A4 induction and de-induction. AAPS J. 2019, 21, 78. [Google Scholar] [CrossRef]
- Jiang, Y.; Zeng, J.; Chen, B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J. Gastroenterol. Hepatol. 2014, 29, 1508–1514. [Google Scholar] [CrossRef]
- Li, Y.A.; Liu, L.B.; Wang, B.A.; Wang, J.A.; Chen, D.A. Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2014, 26, 332–338. [Google Scholar] [CrossRef]
- Shima, T.; Seki, K.; Umemura, A.; Ogawa, R.; Horimoto, R.; Oya, H.; Sendo, R.; Mizuno, M.; Okanoue, T. Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol. Res. 2015, 45, 548–559. [Google Scholar] [CrossRef]
- Le, M.; Devaki, P.; Ha, N.B.; Jun, D.W.; Te, H.S.; Cheung, R.C.; Nguyen, M.H. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE 2017, 12, e0173499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Donato, M.T.; Lahoz, A.; Jimenez, N.; Pérez, G.; Serralta, A.; Mir, J.; Castell, J.V.; Gómez-Lechón, M.J. Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts. Drug Metab. Dispos. 2006, 34, 1556–1562. [Google Scholar] [CrossRef] [PubMed]
- Fisher, C.D.; Lickteig, A.J.; Augustine, L.M.; Ranger-Moore, J.; Jackson, J.P.; Ferguson, S.S.; Cherrington, N.J. Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. Drug Metab. Dispos. 2009, 37, 2087–2094. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Donato, M.T.; Jiménez, N.; Serralta, A.; Mir, J.; Castell, J.V.; Gómez-Lechón, M.J. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol. Vitr. 2007, 21, 271–276. [Google Scholar] [CrossRef] [PubMed]
- Jamwal, R.; de la Monte, S.M.; Ogasawara, K.; Adusumalli, S.; Barlock, B.B.; Akhlaghi, F. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. Mol. Pharm. 2018, 15, 2621–2632. [Google Scholar] [CrossRef]
- Kolwankar, D.; Vuppalanchi, R.; Ethell, B.; Jones, D.R.; Wrighton, S.A.; Hall, S.D.; Chalasani, N. Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity. Clin. Gastroenterol. Hepatol. 2007, 5, 388–393. [Google Scholar] [CrossRef] [PubMed]
- Woolsey, S.J.; Mansell, S.E.; Kim, R.B.; Tirona, R.G.; Beaton, M.D. Cytochrome P450 3A Activity and Expression in Non-Alcoholic Fatty Liver Disease. Drug Metab. Dispos. 2015, 43, 1484–1490. [Google Scholar] [CrossRef] [PubMed]
- Jamwal, R.; Barlock, B.J. Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes. Pharmaceuticals 2020, 13, 222. [Google Scholar] [CrossRef]
- Murphy, W.A.; Adiwidjaja, J.; Sjöstedt, N.; Yang, K.; Beaudoin, J.J.; Spires, J.; Siler, S.Q.; Neuhoff, S.; Brouwer, K.L. Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). Available online: https://www.webofscience.com/wos/woscc/full-record/WOS:000804990500001 (accessed on 20 July 2022).
- Tirona, R.G.; Kassam, Z.; Strapp, R.; Ramu, M.; Zhu, C.; Liu, M.; Schwarz, U.I.; Kim, R.B.; Al-Judaibi, B.; Beaton, M.D. Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metab. Dispos. 2018, 46, 485–492. [Google Scholar] [CrossRef] [Green Version]
- Aruna, T.; Yadav, C.V.B.; Nagabhushanam, M.; Bonthagarala, B.; Reddy, D.N.; Ramakrishna, G. Guidelines for bioavailability and bioequivalence studies: A review. Pharma Innov. J. 2018, 7, 661–666. [Google Scholar]
- El-Khateeb, E.; Darwich, A.S.; Achour, B.; Athwal, V.; Rostami-Hodjegan, A. Review article: Time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment. Pharmacol. Ther. 2021, 54, 388–401. [Google Scholar] [CrossRef]
- Zhuang, X.; Lu, C. PBPK modeling and simulation in drug research and development. Acta Pharm. Sin. B 2016, 6, 430–440. [Google Scholar] [CrossRef] [Green Version]
- Rowland, A.; Miners, J.O.; Mackenzie, P.I. The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. Int. J. Biochem. Cell Biol. 2013, 45, 1121–1132. [Google Scholar] [CrossRef]
- Vildhede, A.; Kimoto, E.; Pelis, R.M.; Rodrigues, A.D.; Varma, M.V.S. Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease. Clin. Pharmacol. Ther. 2020, 107, 1128–1137. [Google Scholar] [CrossRef]
- Kimoto, E.; Mathialagan, S.; Tylaska, L.; Niosi, M.; Lin, J.; Carlo, A.A.; Tess, D.A.; Varma, M.V.S. Organic Anion Transporter 2 mediated Hepatic Uptake Contribute to the Clearance of High Permeability—Low Molecular Weight Acid and Zwitterion Drugs: Evaluation using 25 drugs. J. Pharmacol. Exp. Ther. 2018, 367, 322–334. [Google Scholar] [CrossRef] [Green Version]
- Ferslew, B.C.; Johnston, C.K.; Tsakalozou, E.; Bridges, A.S.; Paine, M.F.; Jia, W.; Stewart, P.W.; Barritt, A.S.; Brouwer, K.L. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin. Pharmacol. Ther. 2015, 97, 419–427. [Google Scholar] [CrossRef] [Green Version]
- Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The Simcyp® Population-based ADME Simulator. Expert. Opin. Drug Metab. Toxicol. 2009, 5, 211–223. [Google Scholar] [CrossRef]
Probe Substrate (Enzyme) | Population | Single Dose | Multiple Doses | ||
---|---|---|---|---|---|
Cmax (ng/mL) | AUC (ng/mL.hr) | Cmax (ng/mL) | AUC (ng/mL.hr) | ||
Caffeine (CYP1A2) | Healthy | 3399 (2190–5481) | 23,712 (8761–57,383) | 3597 (2208–6105) | 25,130 (8774–73,879) |
MAFLD | 3885 (2614–6056) | 50,331 (19,990–97,084) | 5568 (3083–12,856) | 72,715 (20,523–244,322) | |
Ratio ^ | 1.14 | 2.12 # | 1.55 # | 2.89 # | |
Clozapine (CYP1A2) | Healthy | 54.4 (27.2–108) | 436 (209–890) | 58.4 (29.4–109) | 469 (214–1029) |
MAFLD | 62.6 (34.0–127) | 788 (407–1567) | 81.3 (46.6–164) | 1026 (451–2208) | |
Ratio ^ | 1.15 | 1.81 # | 1.39 # | 2.19 # | |
S-Warfarin (CYP2C9) | Healthy | 924 (442–1714) | 15,458 (7879–28,198) | 1877 (801–4499) | 31,630 (11,056–101,358) |
MAFLD | 866 (484–1593) | 15,500 (8577–30,203) | 1983 (897–5000) | 35,778 (12,803–106,346) | |
Ratio ^ | 0.94 | 1.00 | 1.06 | 1.13 | |
Rosiglitazone (CYP2C9) | Healthy | 245 (165–346) | 1152 (385–2378) | 248 (166–352) | 1166 (385–2448) |
MAFLD | 241 (157–366) | 1331 (484–3169) | 247 (158–382) | 1364 (484–3366) | |
Ratio ^ | 0.98 | 1.16 | 0.99 | 1.17 | |
Omeprazole (CYP2C19) | Healthy | 153 (58.0–444) | 467 (110–4505) | 191 (62.0–503) | 666 (120–5130) |
MAFLD | 236 (101–509) | 1174 (253–5528) | 323 (125–777) | 2112 (355–10,090) | |
Ratio ^ | 1.54 # | 2.52 # | 1.70 # | 3.17 # | |
Dextromethorphan (CYP2D6) | Healthy | 4.25 (1.18–20.9) | 49.9 (14.3–393) | 7.56 (2.03–85.2) | 63.6 (15.8–965) |
MAFLD | 5.08 (1.57–18.7) | 66.0 (20.8–383) | 10.1 (2.96–104) | 89.8 (26.4–1170) | |
Ratio ^ | 1.20 # | 1.32 # | 1.33 # | 1.41 # | |
Metoprolol (CYP2D6) | Healthy | 1412 (63.9–366) | 841 (257–4131) | 145 (64.1–385) | 863 (257–4685) |
MAFLD | 172 (85.7–353) | 1223 (425–4208) | 180 (86.2–410) | 1276 (425–5093) | |
Ratio ^ | 1.22 # | 1.45 # | 1.24 # | 1.48 # | |
Midazolam (CYP3A4) | Healthy | 18.7 (5.75–53.6) | 54.7 (14.9–151) | 19.9 (5.89–57.2) | 56.1 (15.2–153) |
MAFLD | 20.7 (8.84–63.5) | 84.8 (23.7–268) | 23.4 (9.09–64.3) | 89.7 (23.8–274) | |
Ratio ^ | 1.11 | 1.55 # | 1.18 | 1.60 # |
Enzyme | Probe Substrate Reaction | Difference ^ | Ref | Geometric Mean Difference ^ |
---|---|---|---|---|
CYP1A2 | 7-methoxyresorufin O-demethylation | 0.46 | [25] | 0.52 |
Phenacetin O-deethylation | 0.58 | [26] | ||
CYP2C9 | Diclofenac 4′-hydroxylation | 0.82 | [25] | 0.96 |
Testosterone 16ß-hydroxlation | 0.64 | [25] | ||
Testosterone 16ß-hydroxlation | 0.40 | [27] | ||
Diclofenac 4′-hydroxylation | 1.53 | [26] | ||
Tolbutamide 4-hydroxylation | 1.42 | [26] | ||
CYP2C19 | Androstenedione | 0.46 | [25] | 0.42 |
Testosterone 16ß-hydroxlation | 0.40 | [27] | ||
Androstenedione | 0.62 | [27] | ||
Mephenytoin 4′hydroxylation | 0.21 | [26] | ||
CYP2D6 | Dextromethorphan O-demethylation | 0.68 | [26] | 0.68 |
CYP3A4 | Midazolam 1′-hydroxylation | 0.45 | [28] | 0.49 |
Testosterone 6ß-hydroxlation | 0.55 | [25] | ||
Testosterone 6ß-hydroxlation | 0.57 | [25] | ||
Testosterone 2ß-hydroxlation | 0.41 | [25] | ||
Testosterone 15ß-hydroxlation | 0.55 | [27] | ||
Testosterone 6ß-hydroxlation | 0.44 | [27] | ||
Testosterone 2ß-hydroxlation | 0.43 | [27] | ||
Testosterone 6ß-hydroxlation | 0.46 | [29] | ||
Midazolam 1′-hydroxylation | 0.41 | [28] | ||
Midazolam 1′-hydroxylation | 0.61 | [30] |
Enzyme | Observed In Vitro Activity Ratio ^ | Simulated Probe Substrate AUC Ratio ^ | Absolute Mean Fold Error # |
---|---|---|---|
CYP1A2 | 1.93 | 2.12 | 1.10 |
CYP2C9 | 1.04 | 1.00 | 1.04 |
CYP2C19 | 2.38 | 2.52 | 1.06 |
CYP2D6 | 1.46 | 1.32 | 1.11 |
CYP3A4 | 2.03 | 1.55 | 1.31 |
Enzyme | Probe Substrate | Parameter | Observed in Animals | Simulated in Humans | Absolute Mean Fold Error # | Ref |
---|---|---|---|---|---|---|
CYP1A2 | Caffeine | AUC ratio | 2.90 | 2.12 | 1.37 | [9] |
Cmax ratio | 2.50 | 1.14 | 2.19 | |||
Clozapine | AUC ratio | 1.20 | 1.81 | 1.50 | [12] | |
Cmax ratio | 0.69 | 1.15 | 1.66 | |||
CYP2C9 | Rosiglitazone | AUC ratio | 2.41 | 1.16 | 2.08 | [10] |
Cmax ratio | 0.86 | 0.982 | 1.14 | |||
CYP2C19 | Omeprazole | AUC ratio | 11.1 | 2.52 | 4.40 | [9] |
Cmax ratio | 6.50 | 1.54 | 4.23 | |||
CYP2D6 | Dextromethorphan | AUC ratio | 2.69 | 1.32 | 2.03 | [9] |
Cmax ratio | 3.31 | 1.20 | 2.77 | |||
Metoprolol | AUC ratio | 2.28 | 1.45 | 1.57 | [11] | |
Cmax ratio | 1.41 | 1.22 | 1.16 | |||
CYP3A4 | Midazolam | AUC ratio | 1.55 | 1.55 | 1.00 | [9] |
Cmax ratio | 1.22 | 1.11 | 1.10 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Newman, E.M.; Rowland, A. A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure. Int. J. Mol. Sci. 2022, 23, 11751. https://doi.org/10.3390/ijms231911751
Newman EM, Rowland A. A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure. International Journal of Molecular Sciences. 2022; 23(19):11751. https://doi.org/10.3390/ijms231911751
Chicago/Turabian StyleNewman, Elise M., and Andrew Rowland. 2022. "A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure" International Journal of Molecular Sciences 23, no. 19: 11751. https://doi.org/10.3390/ijms231911751